Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jacobson PharmaHKSE:02633 -0.96%56 FCF Yield % is 9.28 as of Sep. 02, 2026, which is 51% below its 10-year median of 18.92. GuruFocus rates HKSE:02633 with a GF Score™ of 56/100 and a GF Value™ of HK$0.85 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 1,003 Drug Manufacturers companies, Jacobson Pharma ranks better than 86.64% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Jacobson Pharma FCF Yield % Related Terms
Jacobson Pharma FCF Yield % Historical Data
* Premium members only.
The historical data trend for Jacobson Pharma's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jacobson Pharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jacobson Pharma FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jacobson Pharma's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Jacobson Pharma's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobson Pharma (HKSE:02633) has a FCF Yield % of 9.28 as of Sep. 02, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Jacobson Pharma and its competitors. This is 51% below median its historical median of 18.92. Over the past decade, Jacobson Pharma's FCF Yield % has ranged from 3.40 to 54.96. According to the industry distribution chart, Jacobson Pharma ranks #134 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 13.4%.
Is Jacobson Pharma's FCF Yield % too high?
Jacobson Pharma's current FCF Yield % of 9.28 is 51% below median its 10-year median of 18.92. Over the past 10 years, this metric has ranged from a low of 3.40 to a high of 54.96. The Drug Manufacturers industry median FCF Yield % is 0.75. Jacobson Pharma's value of 9.28 is 1137.3% above this industry median. Based on the distribution chart, Jacobson Pharma ranks #134 out of 1003 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jacobson Pharma has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jacobson Pharma's FCF Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jacobson Pharma ranks #134 out of 1003 companies for FCF Yield %. This places Jacobson Pharma in the top 13% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 0.75. Jacobson Pharma's value of 9.28 is 1137.3% above this benchmark. Historically, Jacobson Pharma's own FCF Yield % has ranged from 3.40 to 54.96 over the past decade. While the company's 10-year median is 18.92 vs. the industry median of 0.75, Jacobson Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.75, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jacobson Pharma's current FCF Yield % of 9.28 is 1137.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Jacobson Pharma and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jacobson Pharma's current FCF Yield % is 9.28, which is 51% below median its own 10-year median of 18.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobson Pharma stock overvalued right now?
Based on GuruFocus' analysis, Jacobson Pharma (HKSE:02633) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$0.85, compared to a current price of HK$1.04 — trading 21.8% above its estimated fair value. The current FCF Yield % is 9.28, which is 51% below median its 10-year median of 18.92 and 1137.3% above the Drug Manufacturers industry median of 0.75. Jacobson Pharma's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Jacobson Pharma (HKSE:02633), the current FCF Yield % is 9.28 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jacobson Pharma (HKSE:02633) Overvalued in 2026?
Based on GuruFocus' analysis, Jacobson Pharma stock appears to be overvalued.
The current stock price of HK$1.04 is trading 21.8% above its estimated GF Value™ of HK$0.85.
GuruFocus considers Jacobson Pharma to be Modestly Overvalued.
Key valuation signals for HKSE:02633:
FCF Yield %: 9.28 (51% below median its 10-year median of 18.92)
GF Value™: HK$0.85 vs. price of HK$1.04 (21.8% above fair value)
Industry Position: 1137.3% above the Drug Manufacturers median (#134 of 1003)
No single metric tells the full story. See the HKSE:02633 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jacobson Pharma Corp Ltd is an investment holding company. It is principally engaged in the development, production, marketing, and sale of generic drugs. The company's operating segment includes Generic drugs; Branded healthcare, Wholesale, and retail The generic drugs segment develops, manufactures, and distributes a host of off-patent medicines for various therapeutic use. It generates maximum revenue from the Generic drugs segment. Geographically, it derives a majority of its revenue from Hong Kong and also has a presence in Mainland China, Macau, Singapore, and Other Countries.
56GF Score
Get the complete analysis for HKSE:02633
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02633 has been successfully added to your 
